CN118679146A - 色胺前药 - Google Patents

色胺前药 Download PDF

Info

Publication number
CN118679146A
CN118679146A CN202280082458.9A CN202280082458A CN118679146A CN 118679146 A CN118679146 A CN 118679146A CN 202280082458 A CN202280082458 A CN 202280082458A CN 118679146 A CN118679146 A CN 118679146A
Authority
CN
China
Prior art keywords
compound
alkyl
linear
branched
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280082458.9A
Other languages
English (en)
Chinese (zh)
Inventor
N·布赖森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruian Neuroscience Co
Original Assignee
Ruian Neuroscience Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruian Neuroscience Co filed Critical Ruian Neuroscience Co
Publication of CN118679146A publication Critical patent/CN118679146A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280082458.9A 2021-12-14 2022-12-08 色胺前药 Pending CN118679146A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289501P 2021-12-14 2021-12-14
US63/289,501 2021-12-14
PCT/CA2022/051797 WO2023108260A1 (en) 2021-12-14 2022-12-08 Tryptamine prodrugs

Publications (1)

Publication Number Publication Date
CN118679146A true CN118679146A (zh) 2024-09-20

Family

ID=86775179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280082458.9A Pending CN118679146A (zh) 2021-12-14 2022-12-08 色胺前药

Country Status (6)

Country Link
US (1) US20250051278A1 (https=)
EP (1) EP4448489A4 (https=)
JP (1) JP2024546138A (https=)
CN (1) CN118679146A (https=)
CA (1) CA3240633A1 (https=)
WO (1) WO2023108260A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551981A1 (en) * 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
CN115867533B (zh) * 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
EP4263504A4 (en) * 2020-12-18 2025-05-14 COMPASS Pathfinder Limited Modified indole alkaloids for therapeutic uses

Also Published As

Publication number Publication date
JP2024546138A (ja) 2024-12-17
US20250051278A1 (en) 2025-02-13
CA3240633A1 (en) 2023-06-22
WO2023108260A1 (en) 2023-06-22
EP4448489A4 (en) 2025-12-31
EP4448489A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
CN115867533B (zh) 色胺前药
JP7184988B2 (ja) チエノピリミジンジオンａｃｃ阻害剤の固体形態およびその生成のための方法
CN118679146A (zh) 色胺前药
US10676438B2 (en) KCNQ2-5 channel activator
EA007008B1 (ru) Триамидзамещённые индолы, бензофураны и бензотиофены в качестве ингибиторов микросомального белка, переносящего триглицериды, (мтр) и/или ингибиторов секреции аполипопротеина в (аро в)
WO1999020620A1 (en) Isoquinoline derivative and drug
WO2018133670A1 (zh) 丁苯酞-替米沙坦杂合物及其制备方法和用途
JP4832897B2 (ja) エステル誘導体及びその医薬用途
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
HK40114252A (zh) 色胺前药
HK40114605A (zh) 色胺前药
HK40114112A (zh) 色胺前药
HK40091294A (zh) 色胺前药
HK40091294B (zh) 色胺前药
ES2465005T3 (es) Derivado de óxido de benzotiofeno y sus sales
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
CN110256461A (zh) 稠杂嘧啶衍生物及其制备方法和应用
CN108558869B (zh) 用于治疗肝癌的化合物及其制剂
JP2005060311A (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40114112

Country of ref document: HK